Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients
Genes · 2024
DOI: 10.3390/genes15060750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Tugce Senturk Kirmizitas und 19 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Center Rotterdam, Department of Medical Oncology, Erasmus MC, 3015 GD Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Epigenesis, Genetic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Glaxo Smith Kline, GlaxoSmithKline.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with advanced-stage epithelial ovarian cancer (EOC) receive treatment with a poly-ADP ribose-polymerase (PARP) inhibitor (PARPi) as maintenance therapy after surgery and chemotherapy. Unfortunately, many patients experience disease progression because of acquired therapy resistance. This study aims to characterize epigenetic and genomic changes in cell-free DNA (cfDNA) associated with PARPi resistance. Materials and Methods: Blood was taken from 31 EOC patients receiving PARPi therapy before treatment and at disease progression during/after treatment. Resistance was defined as disease progression within 6 months after starting PARPi and was seen in fifteen patients, while sixteen patients responded for 6 to 42 months. Blood cfDNA was evaluated via Modified Fast Aneuploidy Screening Test-Sequencing System (mFast-SeqS to detect aneuploidy, via Methylated DNA Sequencing (MeD-seq) to find differentially methylated regions (DMRs), and via shallow whole-genome and -exome sequencing (shWGS, exome-seq) to define tumor fractions and mutational signatures.
Results
Aneuploid cfDNA was undetectable pre-treatment but observed in six patients post-treatment, in five resistant and one responding patient. Post-treatment ichorCNA analyses demonstrated in shWGS and exome-seq higher median tumor fractions in resistant (7% and 9%) than in sensitive patients (7% and 5%). SigMiner analyses detected predominantly mutational signatures linked to mismatch repair and chemotherapy. DeSeq2 analyses of MeD-seq data revealed three methylation signatures and more tumor-specific DMRs in resistant than in responding patients in both pre- and post-treatment samples (274 vs. 30 DMRs, 190 vs. 57 DMRs, Χ2-test p < 0.001).
Conclusion
Our genome-wide Next-Generation Sequencing (NGS) analyses in PARPi-resistant patients identified epigenetic differences in blood before treatment, whereas genomic alterations were more frequently observed after progression. The epigenetic differences at baseline are especially interesting for further exploration as putative predictive biomarkers for PARPi resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Medical Center Rotterdam, Department of Medical Oncology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
- Institute of Graduate Studies in Sciences, Istanbul University, Istanbul 34116, Turkey.
- University Medical Center Rotterdam, Department of Gynecological Oncology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
- University Medical Center Rotterdam, Department of Developmental Biology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
- University Medical Center Rotterdam, Center of Biomics, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
- Department of Molecular Biology & Genetics, Istanbul University, Istanbul 34134, Turkey.
ORCID-Profile: Tugce Senturk Kirmizitas, Caroline van den Berg, Ruben Boers, Jean Helmijr, Stavros Makrodimitris, Jaco Kraan, Wilfred F J van IJcken, Gatske Nieuwenhuyzen-de Boer, Heleen van Beekhuizen, Saskia Wilting, John Martens, Ingrid Boere
Förderung
- Glaxo Smith Kline
- GlaxoSmithKline
Zitieren
APA
Senturk Kirmizitas, T., van den Berg, C., Boers, R., Helmijr, J., Makrodimitris, S., Dag, H. H., Kerkhofs, M., Beaufort, C., Kraan, J., van IJcken, W. F. J., Gribnau, J., Garkhail, P., Boer, G. N., Roes, E. M., van Beekhuizen, H., Gunel, T., Wilting, S., Martens, J., Jansen, M., & Boere, I. (2024). Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients. Genes. https://doi.org/10.3390/genes15060750
Vancouver
Senturk Kirmizitas T, van den Berg C, Boers R, Helmijr J, Makrodimitris S, Dag HH, et al. Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients. Genes. 2024. doi:10.3390/genes15060750
BibTeX
@article{SenturkKirmizitas2024,
author = {Senturk Kirmizitas, Tugce and van den Berg, Caroline and Boers, Ruben and Helmijr, Jean and Makrodimitris, Stavros and Dag, Hamit Harun and Kerkhofs, Marijn and Beaufort, Corine and Kraan, Jaco and van IJcken, Wilfred F J and Gribnau, Joost and Garkhail, Pakriti and Boer, Gatske Nieuwenhuyzen-de and Roes, Eva-Maria and van Beekhuizen, Heleen and Gunel, Tuba and Wilting, Saskia and Martens, John and Jansen, Maurice and Boere, Ingrid},
title = {Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15060750}
}
EUVIMED